Medy Tox Stock Cash Flow From Operations
| 086900 Stock | KRW 128,800 1,600 1.26% |
Medy Tox fundamentals help investors to digest information that contributes to Medy Tox's financial success or failures. It also enables traders to predict the movement of Medy Stock. The fundamental analysis module provides a way to measure Medy Tox's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medy Tox stock.
Medy |
Medy Tox Company Cash Flow From Operations Analysis
Medy Tox's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Medy Tox Cash Flow From Operations | 19.97 B |
Most of Medy Tox's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medy Tox is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Medy Tox has 19.97 B in Cash Flow From Operations. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash flow from operations for all Republic of Korea stocks is notably lower than that of the firm.
Medy Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medy Tox's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medy Tox could also be used in its relative valuation, which is a method of valuing Medy Tox by comparing valuation metrics of similar companies.Medy Tox is rated fifth in cash flow from operations category among its peers.
Medy Fundamentals
| Return On Equity | 0.053 | |||
| Return On Asset | 0.0304 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 989.66 B | |||
| Shares Outstanding | 5.44 M | |||
| Shares Owned By Insiders | 26.72 % | |||
| Shares Owned By Institutions | 10.75 % | |||
| Price To Earning | 57.74 X | |||
| Price To Sales | 3.96 X | |||
| Revenue | 184.87 B | |||
| Gross Profit | 105.47 B | |||
| EBITDA | 45.66 B | |||
| Net Income | 94.15 B | |||
| Cash And Equivalents | 71.77 B | |||
| Total Debt | 55.38 B | |||
| Debt To Equity | 32.80 % | |||
| Current Ratio | 1.03 X | |||
| Book Value Per Share | 21,777 X | |||
| Cash Flow From Operations | 19.97 B | |||
| Earnings Per Share | 1,813 X | |||
| Target Price | 156381.0 | |||
| Number Of Employees | 577 | |||
| Beta | 0.76 | |||
| Market Capitalization | 1 T | |||
| Total Asset | 577.7 B | |||
| Retained Earnings | 131.23 B | |||
| Working Capital | 38 B | |||
| Current Asset | 92.22 B | |||
| Current Liabilities | 54.22 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0 % | |||
| Net Asset | 577.7 B |
About Medy Tox Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medy Tox's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medy Tox using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medy Tox based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medy Tox
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.Moving together with Medy Stock
Moving against Medy Stock
The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medy Stock
Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.